trending Market Intelligence /marketintelligence/en/news-insights/trending/QJP-3exSL2sHdlxLK_6Zrg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Moody's affirms ratings on Hikma Pharmaceuticals

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Moody's affirms ratings on Hikma Pharmaceuticals

Moody's affirmed Hikma Pharmaceuticals PLC's Ba1 corporate family rating, Ba1-PD probability of default rating and the Ba1 instrument rating on its existing senior unsecured bond.

The outlook on all ratings is stable.

Moody's said the affirmation reflects the London-based pharmaceutical company's recent good performance against price pressures, particularly in the U.S., along with a good product pipeline and strong credit metrics due to a conservative balance sheet structure.

According to the rating agency, the positive factors are balanced by Hikma's relatively small scale and moderate margins. Additionally, the rating agency expects a slowdown in growth due to downward pricing pressure in the retail generic market in the U.S.

Moody's also identified political instability in the Middle East and North Africa region along with acquisition-related events as risks for the manufacturer of generic and branded pharmaceuticals.

The rating agency expects Hikma to maintain adjusted gross debt/EBITDA in the range of 1.2x to 1.4x over the next 12 to 18 months, assuming the company refinances a $500 million bond that will mature in April 2020.

Moody's believes the company will not be able to address the bond maturity through available cash. However, Hikma's committed facilities and cash balances will be sufficient to repay the debt.